Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canntab XR
- Development stage
- Phase 3
- Lead developer
- Canntab Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Canntab XR is a proprietary line of solid oral extended-release cannabinoid tablets developed by Canntab Therapeutics. Designed to address the dosing inaccuracies, variable bioavailability, and short duration of action associated with traditional medical cannabis delivery methods (such as smoking, vaping, or edibles), Canntab XR tablets utilize a sustained-release core surrounded by a protective coating. This formulation delivers a standardized, consistent dose of active phytocannabinoids—specifically cannabidiol (CBD), tetrahydrocannabinol (THC), or a combination of both (such as a 5:1 CBD:THC ratio)—over a 12- to 18-hour period. By providing a steady therapeutic level of cannabinoids in the bloodstream, Canntab XR aims to minimize side effects and improve patient compliance in the management of chronic conditions requiring prolonged treatment, such as chronic pain, post-traumatic stress disorder (PTSD), fibromyalgia, and sleep disorders.
- Brand names
- Canntab XR
- Other names
- Canntab Extended Release tabletExtended Release cannabinoid tablet
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Canntab XR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canntab XR.